Noninvasive tools to assess liver disease

Current Opinion in Gastroenterology

Volumn 26, Issue 3, 2010, Pages 227-233

  Patel, Keyur ^a  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

Author keywords

Biomarkers; Biopsy; Elastography; Fibrosis; Imaging

Indexed keywords

SMOOTH MUSCLE ACTIN;

ALGORITHM; DISEASE COURSE; ELASTOGRAPHY; GENETIC MARKER; HEPATITIS C; HISTOLOGY; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER DISEASE; LIVER FIBROSIS; MICROSCOPY; NONALCOHOLIC FATTY LIVER; PROTEIN STRUCTURE; PROTEOMICS; REVIEW;

BIOLOGICAL MARKERS; HUMANS; LIVER DISEASES; PROGNOSIS;

EID: 77951273663     PISSN: 02671379     EISSN: None     Source Type: Journal    
DOI: 10.1097/MOG.0b013e3283383c68     Document Type: Review

References (49)

1. Rockey DC, Caldwell SH, Goodman ZD, et al. Liver biopsy. Hepatology 2009; 49:1017-1044.
2. McHutchison J, Poynard T, Afdhal N. Fibrosis as an end point for clinical trials in liver disease: a report of the international fibrosis group. Clin Gastroenterol Hepatol 2006; 4:1214-1220. (Pubitemid 44512218)
3. Popov Y, Schuppan D. Targeting liver fibrosis: strategies for development and validation of antifibrotic therapies. Hepatology 2009; 50:1294-1306.
4. Smith JO, Sterling RK. Systematic review: noninvasive methods of fibrosis analysis in chronic hepatitis C. Aliment Pharmacol Ther 2009; 30:557-576.
5. Sebastiani G. Noninvasive assessment of liver fibrosis in chronic liver diseases: implementation in clinical practice and decisional algorithms. World J Gastroenterol 2009; 15:2190-2203.
6. Manning DS, Afdhal NH. Diagnosis and quantitation of fibrosis. Gastroenterology 2008; 134:1670-1681.
7. Poynard T, Muntenau M, Morra R, et al. Methodological aspects of the interpretation of noninvasive biomarkers of liver fibrosis: a 2008 update. Gastroenterol Clin Biol 2008; 32:8-21.
8. Lambert J, Halfon P, Penaranda G, et al. How to measure the diagnostic accuracy of noninvasive liver fibrosis indices: the area under the ROC curve revisited. Clin Chem 2008; 54:1372-1378.
9. Cales P, de Ledinghen V, Halfon P, et al. Evaluating the accuracy and increasing the reliable diagnosis rate of blood tests for liver fibrosis in chronic hepatitis C. Liver Int 2008; 28:1352-1362.
10. Rousselet MC, Michalak S, Dupre F, et al. Sources of variability in histological scoring of chronic viral hepatitis. Hepatology 2005; 41:257-264. (Pubitemid 40165369)
11. Bedossa P, Dargere D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003; 38:1449-1457. (Pubitemid 37466971)
12. Goodman ZD, Stoddard AM, Bonkovsky HL, et al. Fibrosis progression in chronic hepatitis C: morphometric image analysis in the HALT-C trial. Hepatology 2009; 50:1738-1749.
13. McHutchison J, Goodman Z, Patel K, et al. Farglitizar lacks antifibrotic activity in patients with chronic hepatitis C infection. Gastroenterology (in press).
14. Sun W, Chang S, Tai DC, et al. Nonlinear optical microscopy: use of second harmonic generation and two-photon microscopy for automated quantitative liver fibrosis studies. J Biomed Opt 2008; 13:064010.
15. Gressner AM, Gao CF, Gressner OA. Noninvasive biomarkers for monitoring the fibrogenic process in liver: a short survey. World J Gastroenterol 2009; 15:2433-2440.
16. Becker L, Salameh W, Sferruzza A, et al. Validation of Hepascore, compared with simple indices of fibrosis, in patients with chronic hepatitis C virus infection in United States. Clin Gastroenterol Hepatol 2009; 7:696-701.
17. Bottero J, Lacombe K, Guechot J, et al. Performance of 11 biomarkers for liver fibrosis assessment in HIV/HBV co-infected patients. J Hepatol 2009; 50:1074-1083.
18. Shah AG, Lydecker A, Murray K, et al. Comparison of noninvasive markers of fibrosis in patients with nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2009; 7:1104-1112.
19. Parkes J, Guha IN, Roderick P, Rosenberg W. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006; 44:462-474. (Pubitemid 43227870)
20. Patel K, Benhamou Y, Yoshida EM, et al. An independent and prospective comparison of two commercial fibrosis marker panels (HCV FibroSURE and FIBROSpect II) during albinterferon alfa-2b combination therapy for chronic hepatitis C. J Viral Hepat 2009; 16:178-186.
21. Fontana RJ, Bonkovsky HL, Naishadham D, et al. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis. Clin Gastroenterol Hepatol 2009; 7:219-226.
22. Myers RP. Noninvasive diagnosis of nonalcoholic fatty liver disease. Ann Hepatol 2009; 8 (Suppl 1):S25-S33.
23. Cales P, Laine F, Boursier J, et al. Comparison of blood tests for liver fibrosis specific or not to NAFLD. J Hepatol 2009; 50:165-173.
24. Sebastiani G, Halfon P, Castera L, et al. SAFE biopsy: a validated method for large-scale staging of liver fibrosis in chronic hepatitis C. Hepatology 2009; 49:1821-1827.
25. Paggi S, Colli A, Fraquelli M, et al. A noninvasive algorithm accurately predicts advanced fibrosis in hepatitis C: a comparison using histology with internalexternal validation. J Hepatol 2008; 49:564-571.
26. Vanderschaeghe D, Laroy W, Sablon E, et al. GlycoFibroTest is a highly performant liver fibrosis biomarker derived from DNA sequencer-based serum protein glycomics. Mol Cell Proteomics 2009; 8:986-994.
27. Chen C, Schmilovitz-Weiss H, Liu XE, et al. Serum protein N-glycans profiling for the discovery of potential biomarkers for nonalcoholic steatohepatitis. J Proteome Res 2009; 8:463-470.
28. Morra R, Munteanu M, Bedossa P, et al. Diagnostic value of serum protein profiling by SELDI-TOF ProteinChip compared with a biochemical marker, FibroTest, for the diagnosis of advanced fibrosis in patients with chronic hepatitis C. Aliment Pharmacol Ther 2007; 26:847-858. (Pubitemid 47346704)
29. Cheung KJ, Tilleman K, Deforce D, et al. The HCV serum proteome: a search for fibrosis protein markers. J Viral Hepat 2009; 16:418-429.
30. Molleken C, Sitek B, Henkel C, et al. Detection of novel biomarkers of liver cirrhosis by proteomic analysis. Hepatology 2009; 49:1257-1266.
31. Huang H, Shiffman ML, Cheung RC, et al. Identification of two gene variants associated with risk of advanced fibrosis in patients with chronic hepatitis C. Gastroenterology 2006; 130:1679-1687. (Pubitemid 43668836)
32. Huang H, Shiffman ML, Friedman S, et al. A 7 gene signature identifies the risk of developing cirrhosis in patients with chronic hepatitis C. Hepatology 2007; 46:297-306. (Pubitemid 47344763)
33. Marcolongo M, Young B, Dal Pero F, et al. A seven-gene signature (cirrhosis risk score) predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50:1038-1044.
34. Pradat P, Trepo E, Potthoff A, et al. The cirrhosis risk score predicts liver fibrosis progression in patients with initially mild chronic hepatitis C. Hepatology 2009; 50:1038-1044.
35. Asselah T, Bieche I, Laurendeau I, et al. Significant gene expression differences in histologically 'Normal' liver biopsies: implications for control tissue. Hepatology 2008; 48:953-962.
36. Mehta SH, Lau B, Afdhal NH, Thomas DL. Exceeding the limits of liver histology markers. J Hepatol 2009; 50:36-41.
37. Ngo Y, Munteanu M, Messous D, et al. A prospective analysis of the prognostic value of biomarkers (FibroTest) in patients with chronic hepatitis C. Clin Chem 2006; 52:1887-1896. (Pubitemid 44470696)
38. Mayo MJ, Parkes J, Adams-Huet B, et al. Prediction of clinical outcomes in primary biliary cirrhosis by serum enhanced liver fibrosis assay. Hepatology 2008; 48:1549-1557.
39. Ghany MG, Lok AS, Everhart JE, et al. Predicting clinical and histologic outcomes based on standard laboratory tests in advanced chronic hepatitis C. Gastroenterology 2010; 138:136-146.
40. Friedrich-Rust M, Ong MF, Martens S, et al. Performance of transient elastography for the staging of liver fibrosis: a meta-analysis. Gastroenterology 2008; 134:960-974. (Pubitemid 351451980)
41. Castera L, Forns X, Alberti A. Noninvasive evaluation of liver fibrosis using transient elastography. J Hepatol 2008; 48:835-847. (Pubitemid 351224001)
42. Boursier J, Vergniol J, Sawadogo A, et al. The combination of a blood test and Fibroscan improves the noninvasive diagnosis of liver fibrosis. Liver Int 2009; 29:1507-1515.
43. Vizzutti F, Arena U, Romanelli RG, et al. Liver stiffness measurement predicts severe portal hypertension in patients with HCV-related cirrhosis. Hepatology 2007; 45:1290-1297. (Pubitemid 46775793)
44. Fontaine H, Petitprez K, Roudot-Thoraval F, Trinchet JC. Guidelines for the diagnosis of uncomplicated cirrhosis. Gastroenterol Clin Biol 2007; 31:504-509. (Pubitemid 46877550)
45. Takahashi H, Ono N, Eguchi Y, et al. Evaluation of acoustic radiation force impulse elastography for fibrosis staging of chronic liver disease: a pilot study. Liver Int (in press), doi:10.1111/j.1478-3231.2009.02130.x
46. Talwalkar JA, Yin M, Fidler JL, et al. Magnetic resonance imaging of hepatic fibrosis: emerging clinical applications. Hepatology 2008; 47:332-342. (Pubitemid 351171070)
47. Huwart L, Sempoux C, Vicaut E, et al. Magnetic resonance elastography for the noninvasive staging of liver fibrosis. Gastroenterology 2008; 135:32-40. (Pubitemid 351899024)
48. Dinesen L, Caspary WF, Chapman RW, et al. 13C-methacetin-breath test compared to also noninvasive biochemical blood tests in predicting hepatic fibrosis and cirrhosis in chronic hepatitis C. Dig Liver Dis 2008; 40:743-748.
49. Lalazar G, Adar T, Ilan Y. Point-of-care continuous (13)C-methacetin breath test improves decision making in acute liver disease: results of a pilot clinical trial. World J Gastroenterol 2009; 15:966-972.